{"name":"Baxalta now part of Shire","slug":"baxalta-now-part-of-shire","ticker":"","exchange":"","domain":"baxaltanowpartofshire.com","description":"","hq":"Bannockburn","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"ITI","genericName":"ITI","slug":"iti","indication":"Hemophilia A with factor VIII inhibitors","status":"marketed"},{"name":"BAX855","genericName":"BAX855","slug":"bax855","indication":"Hemophilia A (on-demand and prophylactic treatment)","status":"phase_3"},{"name":"RIXUBIS: Prophylaxis","genericName":"RIXUBIS: Prophylaxis","slug":"rixubis-prophylaxis","indication":"Prophylaxis of bleeding episodes in patients with hemophilia B (Factor IX deficiency)","status":"marketed"},{"name":"Recombinant factor IX","genericName":"Recombinant factor IX","slug":"recombinant-factor-ix","indication":"Hemophilia B (factor IX deficiency) — prevention and treatment of bleeding episodes","status":"marketed"},{"name":"ADYNOVI","genericName":"ADYNOVI","slug":"adynovi","indication":"Hemophilia A, prevention and treatment of bleeding episodes","status":"phase_2"},{"name":"BAX 326","genericName":"BAX 326","slug":"bax-326","indication":"Hemophilia A (treatment and prophylaxis of bleeding episodes)","status":"phase_3"},{"name":"OBIZUR","genericName":"OBIZUR","slug":"obizur","indication":"Hemophilia A (congenital Factor VIII deficiency) for routine prophylaxis and on-demand treatment of bleeding episodes","status":"marketed"},{"name":"PEGylated Recombinant Factor VIII","genericName":"PEGylated Recombinant Factor VIII","slug":"pegylated-recombinant-factor-viii","indication":"Hemophilia A, for the prevention and control of bleeding episodes","status":"phase_3"},{"name":"RIXUBIS: On-Demand","genericName":"RIXUBIS: On-Demand","slug":"rixubis-on-demand","indication":"Hemophilia B (Factor IX deficiency) — on-demand treatment and control of bleeding episodes","status":"marketed"},{"name":"Recombinant Factor VIII (rAHF)","genericName":"Recombinant Factor VIII (rAHF)","slug":"recombinant-factor-viii-rahf","indication":"Hemophilia A (congenital Factor VIII deficiency) — treatment and prevention of bleeding episodes","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"Aerosolized, Recombinant Alpha 1-Antitrypsin","genericName":"Aerosolized, Recombinant Alpha 1-Antitrypsin","slug":"aerosolized-recombinant-alpha-1-antitrypsin","indication":"Other","status":"phase_1"},{"name":"AskBio009","genericName":"AskBio009","slug":"askbio009","indication":"Other","status":"phase_1"},{"name":"RIXUBIS","genericName":"RIXUBIS","slug":"rixubis","indication":"Other","status":"marketed"},{"name":"ARALAST Alpha1-Proteinase Inhibitor","genericName":"ARALAST Alpha1-Proteinase Inhibitor","slug":"aralast-alpha1-proteinase-inhibitor","indication":"Other","status":"marketed"},{"name":"CUVITRU","genericName":"CUVITRU","slug":"cuvitru","indication":"Other","status":"marketed"},{"name":"KIOVIG","genericName":"KIOVIG","slug":"kiovig","indication":"Other","status":"marketed"},{"name":"Placebo: Human albumin 2.5%","genericName":"Placebo: Human albumin 2.5%","slug":"placebo-human-albumin-2-5","indication":"Hypovolemia and shock (hemorrhagic, septic, or traumatic)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"infectious","drugs":[{"name":"IGIV GAMMAGARD LIQUID/KIOVIG","genericName":"IGIV GAMMAGARD LIQUID/KIOVIG","slug":"igiv-gammagard-liquid-kiovig","indication":"Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)","status":"phase_3"},{"name":"IGIV GAMUNEX®-C","genericName":"IGIV GAMUNEX®-C","slug":"igiv-gamunex-c","indication":"Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)","status":"phase_3"},{"name":"IV treatment with IGSC, 10%","genericName":"IV treatment with IGSC, 10%","slug":"iv-treatment-with-igsc-10","indication":"Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Alpha1-Proteinase Inhibitor","genericName":"Alpha1-Proteinase Inhibitor","slug":"alpha1-proteinase-inhibitor","indication":"Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease (COPD)","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"BAX326","genericName":"BAX326","slug":"bax326","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_2"}]}],"pipeline":[{"name":"ITI","genericName":"ITI","slug":"iti","phase":"marketed","mechanism":"ITI is an immune tolerance induction therapy that uses a combination of immunosuppressive agents to induce tolerance to factor VIII in hemophilia A patients with inhibitors.","indications":["Hemophilia A with factor VIII inhibitors"],"catalyst":""},{"name":"Aerosolized, Recombinant Alpha 1-Antitrypsin","genericName":"Aerosolized, Recombinant Alpha 1-Antitrypsin","slug":"aerosolized-recombinant-alpha-1-antitrypsin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AskBio009","genericName":"AskBio009","slug":"askbio009","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BAX855","genericName":"BAX855","slug":"bax855","phase":"phase_3","mechanism":"BAX855 is a recombinant factor VIII (antihemophilic factor) fused to the Fc portion of human immunoglobulin G1 to extend half-life and improve hemostasis in hemophilia A.","indications":["Hemophilia A (on-demand and prophylactic treatment)"],"catalyst":""},{"name":"RIXUBIS","genericName":"RIXUBIS","slug":"rixubis","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"RIXUBIS: Prophylaxis","genericName":"RIXUBIS: Prophylaxis","slug":"rixubis-prophylaxis","phase":"marketed","mechanism":"Rixubis is a recombinant Factor IX (prothrombin complex component) that replaces deficient clotting factor to restore the intrinsic coagulation pathway.","indications":["Prophylaxis of bleeding episodes in patients with hemophilia B (Factor IX deficiency)","On-demand treatment of bleeding episodes in hemophilia B"],"catalyst":""},{"name":"Recombinant factor IX","genericName":"Recombinant factor IX","slug":"recombinant-factor-ix","phase":"marketed","mechanism":"Recombinant factor IX replaces the missing or deficient clotting factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation.","indications":["Hemophilia B (factor IX deficiency) — prevention and treatment of bleeding episodes","Hemophilia B — perioperative management and surgical prophylaxis"],"catalyst":""},{"name":"ADYNOVI","genericName":"ADYNOVI","slug":"adynovi","phase":"phase_2","mechanism":"ADYNOVI is a recombinant human coagulation factor VIII, used to treat and prevent bleeding episodes in patients with hemophilia A.","indications":["Hemophilia A, prevention and treatment of bleeding episodes"],"catalyst":""},{"name":"ARALAST Alpha1-Proteinase Inhibitor","genericName":"ARALAST Alpha1-Proteinase Inhibitor","slug":"aralast-alpha1-proteinase-inhibitor","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alpha1-Proteinase Inhibitor","genericName":"Alpha1-Proteinase Inhibitor","slug":"alpha1-proteinase-inhibitor","phase":"marketed","mechanism":"Alpha1-proteinase inhibitor (AAT) replaces deficient or dysfunctional alpha-1 antitrypsin protein to protect lung tissue from enzymatic degradation.","indications":["Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease (COPD)","Alpha-1 antitrypsin deficiency with progressive lung disease"],"catalyst":""},{"name":"BAX 326","genericName":"BAX 326","slug":"bax-326","phase":"phase_3","mechanism":"BAX 326 is a recombinant human coagulation factor VIII designed to treat hemophilia A by replacing deficient or dysfunctional factor VIII.","indications":["Hemophilia A (treatment and prophylaxis of bleeding episodes)"],"catalyst":""},{"name":"BAX326","genericName":"BAX326","slug":"bax326","phase":"phase_2","mechanism":"BAX326 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"CUVITRU","genericName":"CUVITRU","slug":"cuvitru","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IGIV GAMMAGARD LIQUID/KIOVIG","genericName":"IGIV GAMMAGARD LIQUID/KIOVIG","slug":"igiv-gammagard-liquid-kiovig","phase":"phase_3","mechanism":"IGIV (intravenous immunoglobulin) provides passive immunity by supplying pooled human antibodies to replace or supplement deficient or dysfunctional immunoglobulin in patients with immune deficiencies or autoimmune conditions.","indications":["Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)","Secondary immunodeficiency in hematologic malignancies","Chronic inflammatory demyelinating polyneuropathy (CIDP)","Multifocal motor neuropathy","Idiopathic thrombocytopenic purpura (ITP)"],"catalyst":""},{"name":"IGIV GAMUNEX®-C","genericName":"IGIV GAMUNEX®-C","slug":"igiv-gamunex-c","phase":"phase_3","mechanism":"IGIV Gamunex-C is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to help patients fight infections and modulate immune responses.","indications":["Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)","Secondary immunodeficiency in hematologic malignancies","Chronic inflammatory demyelinating polyneuropathy (CIDP)","Multifocal motor neuropathy (MMN)"],"catalyst":""},{"name":"IV treatment with IGSC, 10%","genericName":"IV treatment with IGSC, 10%","slug":"iv-treatment-with-igsc-10","phase":"phase_3","mechanism":"IGSC 10% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by supplying pooled human antibodies to help regulate immune function and fight infections.","indications":["Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)","Secondary immunodeficiencies","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"KIOVIG","genericName":"KIOVIG","slug":"kiovig","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"OBIZUR","genericName":"OBIZUR","slug":"obizur","phase":"marketed","mechanism":"OBIZUR is a recombinant human Factor VIII that replaces deficient or dysfunctional Factor VIII to restore blood clotting ability in patients with hemophilia A.","indications":["Hemophilia A (congenital Factor VIII deficiency) for routine prophylaxis and on-demand treatment of bleeding episodes"],"catalyst":""},{"name":"PEGylated Recombinant Factor VIII","genericName":"PEGylated Recombinant Factor VIII","slug":"pegylated-recombinant-factor-viii","phase":"phase_3","mechanism":"PEGylated Recombinant Factor VIII is a recombinant form of human factor VIII that is modified with polyethylene glycol (PEG) to prolong its half-life.","indications":["Hemophilia A, for the prevention and control of bleeding episodes","Surgery in patients with hemophilia A"],"catalyst":""},{"name":"Placebo: Human albumin 2.5%","genericName":"Placebo: Human albumin 2.5%","slug":"placebo-human-albumin-2-5","phase":"marketed","mechanism":"Human albumin 2.5% acts as a volume expander and oncotic agent to maintain intravascular fluid balance and plasma colloid osmotic pressure.","indications":["Hypovolemia and shock (hemorrhagic, septic, or traumatic)","Hypoproteinemia and edema management","Plasma volume expansion during major surgery or critical illness"],"catalyst":""},{"name":"RIXUBIS: On-Demand","genericName":"RIXUBIS: On-Demand","slug":"rixubis-on-demand","phase":"marketed","mechanism":"RIXUBIS is a recombinant Factor IX that replaces deficient or dysfunctional clotting factor IX to restore blood coagulation in patients with hemophilia B.","indications":["Hemophilia B (Factor IX deficiency) — on-demand treatment and control of bleeding episodes"],"catalyst":""},{"name":"Recombinant Factor VIII (rAHF)","genericName":"Recombinant Factor VIII (rAHF)","slug":"recombinant-factor-viii-rahf","phase":"marketed","mechanism":"Recombinant Factor VIII replaces the missing or deficient clotting factor VIII protein to restore the intrinsic coagulation pathway and enable normal blood clot formation.","indications":["Hemophilia A (congenital Factor VIII deficiency) — treatment and prevention of bleeding episodes","Perioperative management in hemophilia A patients"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPby1IWl9NQm9ORGlmZDRfdnE3TnExZnVHSVJWTnlWSlRER0dsdGFKckg2em1XMTY5OHhjSWdHcnVaeDN4OG82Ti1Ua0duMlFiRmhTNlRxMS1FaFVsUkVDLXE0bHYtRE1KVzl3NFlkNzVXQVRqNThDU055cUVjd1p5a3htSDhQSEN0bkg2MnpweHlGY09nLUlJamN3?oc=5","date":"2021-07-02","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Baxalta and Momenta part ways on adalimumab biosimilar - Generics and Biosimilars Initiative","headline":"Baxalta and Momenta part ways on adalimumab biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPTjNFeTNsMktGMlprOFB3VjI5UzVoNDFqVUtPZEFiSkx6Qk5nZlVGdHRTZGQyVm5qc1RBdHBmUWg5UHNjOGpaaUJhamFjRENMY2dreGxLSTJINEc0UG5HMEhjd2lTRk1qeEZDNk1LUUNYRXVrdlJpVW9sUVZfbUZqdURIMEJGWkxhbHcxX0VfSjVyRWJ5eFhHQ3I5UklVR0RM?oc=5","date":"2019-01-23","type":"pipeline","source":"DCAT Value Chain Insights","summary":"The $62-Billion Marriage of Shire and Takeda: The Risks and Rewards - DCAT Value Chain Insights","headline":"The $62-Billion Marriage of Shire and Takeda: The Risks and Rewards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNNE9iQzdrOUZCWUlpWktMb183dk92alg1Q3h5Zzh1dDFpOXlWc3hib0pGanV3ZjMzeWduWUo5ZGk1OUV1R3k2VlJIU25LVUZIcGpKODBPUUVqbGdLYm9fb1NaSzRMeXpZVXliRDdSUFVRRFEtaUpyVFpoNU9KT3JkY0hsTjB4NC1UX2FhVnJWbGs5b2RhcGE4QjVOM0x3TTBHZUdtbHhDaWV5Rm14X2dv?oc=5","date":"2017-08-30","type":"pipeline","source":"Fierce Pharma","summary":"Shire disputes employee dissatisfaction report as UBS slashes price target - Fierce Pharma","headline":"Shire disputes employee dissatisfaction report as UBS slashes price target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcXhFbjd3bnpuMEw1R0QyWDFZdExaSjdEdl9SZU1ZZGdWaG1mM1VOeHhOUkJYc1VaSWp1bkFfaUl2UklQYWN5MWtCV2YxZXhMQlczT25yN0lRWHlScU1PUVpZcEFZaTAtMXRmWmJYNFdUWmNQUmdSN25TaEdRdndybjB5Si01RC1YemJkSDFKSzdwU1B0NlFuWFZ6bVlBSnprNmE3cUpuazQ1Zw?oc=5","date":"2016-07-11","type":"deal","source":"Fierce Biotech","summary":"After Baxalta-Shire merger, David Meek lands CEO job at leaderless Ipsen - Fierce Biotech","headline":"After Baxalta-Shire merger, David Meek lands CEO job at leaderless Ipsen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNZnBRSHNtT2lZUXdQalBJd0lTS0J1WjNvUk40cTJsTnQtanc5MGNWX2RQWXY2d19leXdaM2RlMnFYU0lDUXhMMnVpOFpZYVl4YkRoUTFtS1ZMakF0elhGYmpUZEY4Sjl4MU9hVG50S24xOFVEYzJEU0c0S0dXb0wyM1RlTW01RHExYmR5bnlGeElxLUthRWlERmNqcw?oc=5","date":"2016-04-15","type":"pipeline","source":"Fierce Pharma","summary":"Shire building $400M biologics plant, adding 400 jobs in Ireland - Fierce Pharma","headline":"Shire building $400M biologics plant, adding 400 jobs in Ireland","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9MNjlUX0piQ3RiYVpXeThnd0ZCRXA3REFSM2RsSGJvSHNYRWxTNW92NFFIRlpVcEtJYnRvb3FHbEIwNlBJUkk0SVB0Z2p1T3hMajlvVDRjLUl0a0xiYkVuWmloSmg?oc=5","date":"2016-03-03","type":"pipeline","source":"Thousand Oaks Acorn","summary":"Axe drops at Baxalta - Thousand Oaks Acorn","headline":"Axe drops at Baxalta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQREw1dUF2SVctODJyQ2xGQXZSM0dVeHNHNmljRFFYNFdkVGUwd2RoLTdPcE5sT0R6OUtIdnRnVnlYdE1UUUhrYk5DcXJHMEplZUw1NlpuekxDbl9CRjJoTkhQRjZYUElGcUNENW5mTW96UXZsakdhZS1ybDhvaU1kSGgtbl9zVjJzVWN1SFR3Z2h1czZWYWpmU0QxcWRCTkpnRWtlSF9R?oc=5","date":"2016-01-14","type":"pipeline","source":"BioPharma Dive","summary":"Analysts skeptical about Shire’s Baxalta ‘growth play’ strategy - BioPharma Dive","headline":"Analysts skeptical about Shire’s Baxalta ‘growth play’ strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQcGZXeEZVN3dCajZyMFU1cVVHVW5aY0QwT1B5X0hpN2gwTU52T0xicEtnOFVoWUVFNjJKSFNqdHcwMkRmZjBxUkEtTHZMWUFtb3REREFEWWRpOEZqVkxmY1RUdThtOEhETDZkWTZDLWk0eElMSEs4M205b0dmQTJ1c3QzaGVDQmhBZTlZakxQRnZ2YmJoZTZUeWJzN0pCdm82bkZqSnFIcmh5c2R4REtxbEdEczhidw?oc=5","date":"2016-01-11","type":"deal","source":"The New York Times","summary":"Shire-Baxalta Merger Will Create a Giant in Drugs for Rare Diseases (Published 2016) - The New York Times","headline":"Shire-Baxalta Merger Will Create a Giant in Drugs for Rare Diseases (Published 2016)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5iNldJdGpKdVE2QlNsVTUyZEZlOE93WkFsbERDN19YRmxsOE4xZVl0UXhxWWNyd1RRTkhWUE01Smh1RTA0Q3pXcFV1Z3pVSDYwMTgwWQ?oc=5","date":"2016-01-11","type":"deal","source":"BBC","summary":"Shire strikes $32bn deal for US drugs rival Baxalta - BBC","headline":"Shire strikes $32bn deal for US drugs rival Baxalta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNRDRWY3BETjMwOE9Ebm5YODBRTjVvTng4Vzk5WnVNRE11TjFOUzhCeW53Yml2Wk1zQXJYMUNuQ0JWUjAtY3RkaWpCaGZGekIwXzB2TjFFa3lwTHZBOVNiNWFHUFhBeTZBcVBxOWFoZld1MXZDZnd3eWJya2dJeS1WY0tReVlTNmN3cWVKRlJGdU5NUQ?oc=5","date":"2016-01-11","type":"deal","source":"USA Today","summary":"Shire to buy Baxalta for $32B - USA Today","headline":"Shire to buy Baxalta for $32B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNQWRkS0JNNEhhRDZvQzZIdmlTTFh1a2RsdV9XV3pWWmNsR0luaDVSWE13LXlRbWJJSDZxQmF3WmxqdkFESDBYcUNpLVhOaVR2NjRmeU9Ba0N3VERfSjlsWnJKd3ktYTlaX2o5bUFNLURCc0IyX0dBUE4yc0VQVGM0aHA1Y1J0WXM?oc=5","date":"2016-01-04","type":"deal","source":"Pharmafile","summary":"Reports: $32bn Shire takeover of Baxalta close to done deal - Pharmafile","headline":"Reports: $32bn Shire takeover of Baxalta close to done deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZi0tcTFaZzh1X0puRzNic0M5d3hWQVdyelBhOWRqT3Racy1yV1NEUFRHbHQ5Q0hub3FNaTNhZVNuemlpZDhMSEVoT1VINmtfaWJHcVBBeEJpSmE1cG42dUI1a2RUdlRkMFlzTTdqbWhPSTJjZWNmaTdUSURzbEtKanVrZmFJblZpNjh4SXhxWFNMT0Rm?oc=5","date":"2015-08-05","type":"pipeline","source":"Contract Pharma","summary":"Shire Makes Unsolicited $30.6B Bid for Baxalta - Contract Pharma","headline":"Shire Makes Unsolicited $30.6B Bid for Baxalta","sentiment":"neutral"}],"patents":[],"drugCount":22,"phaseCounts":{"marketed":12,"phase_1":2,"phase_3":6,"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}